Derivation and validation of cutoffs for clinical use of cell cycle arrest biomarkers

Acute kidney injury (AKI) remains a deadly condition. Tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein (IGFBP)7 are two recently discovered urinary biomarkers for AKI. We now report on the development, and diagnostic accuracy of two clinical cutoffs for...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Nephrology, dialysis, transplantation Ročník 29; číslo 11; s. 2054
Hlavní autori:	Hoste, Eric A J, McCullough, Peter A, Kashani, Kianoush, Chawla, Lakhmir S, Joannidis, Michael, Shaw, Andrew D, Feldkamp, Thorsten, Uettwiller-Geiger, Denise L, McCarthy, Paul, Shi, Jing, Walker, Michael G, Kellum, John A
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England 01.11.2014
Predmet:	Acute Kidney Injury - pathology Acute Kidney Injury - urine Aged Biomarkers - urine Cell Cycle Checkpoints - physiology Female Follow-Up Studies Humans Insulin-Like Growth Factor Binding Proteins - urine Male Middle Aged Predictive Value of Tests ROC Curve Tissue Inhibitor of Metalloproteinase-2 - urine insulin-like growth factor binding protein (IGFBP)7 and tissue inhibitor of metalloproteinases (TIMP)-2 acute kidney injury acute renal failure sensitivity and specificity (MeSH) biomarkers
ISSN:	1460-2385, 1460-2385
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Acute kidney injury (AKI) remains a deadly condition. Tissue inhibitor of metalloproteinases (TIMP)-2 and insulin-like growth factor binding protein (IGFBP)7 are two recently discovered urinary biomarkers for AKI. We now report on the development, and diagnostic accuracy of two clinical cutoffs for a test using these markers. We derived cutoffs based on sensitivity and specificity for prediction of Kidney Disease: Improving Global Outcomes Stages 2-3 AKI within 12 h using data from a previously published multicenter cohort (Sapphire). Next, we verified these cutoffs in a new study (Opal) enrolling 154 critically ill adults from six sites in the USA. One hundred subjects (14%) in Sapphire and 27 (18%) in Opal met the primary end point. The results of the Opal study replicated those of Sapphire. Relative risk (95% CI) in both studies for subjects testing at ≤0.3 versus >0.3-2 were 4.7 (1.5-16) and 4.4 (2.5-8.7), or 12 (4.2-40) and 18 (10-37) for ≤0.3 versus >2. For the 0.3 cutoff, sensitivity was 89% in both studies, and specificity 50 and 53%. For 2.0, sensitivity was 42 and 44%, and specificity 95 and 90%. Urinary [TIMP-2]•[IGFBP7] values of 0.3 or greater identify patients at high risk and those >2 at highest risk for AKI and provide new information to support clinical decision-making. Clintrials.gov # NCT01209169 (Sapphire) and NCT01846884 (Opal).
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3
ISSN:	1460-2385 1460-2385
DOI:	10.1093/ndt/gfu292